Sobi to present new gout data at ACR Convergence 2026

Sobi highlights upcoming Phase 3 gout therapy data but reveals no new clinical results.

What the company is saying

Sobi is announcing that six abstracts on its investigational gout therapies, pozdeutinurad (AR882) and NASP, will be presented at ACR Convergence 2026 in Orlando from 6–11 November 2026. The company emphasizes its ongoing Phase 3 clinical programs, including the REDUCE-2 study for pozdeutinurad and the DISSOLVE I/II trials for NASP, as well as real-world and patient preference research in the United States. Lydia Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer, frames the narrative as patient-focused and research-driven, aiming to address unmet needs in uncontrolled gout. The announcement details the timing and topics of both oral and poster presentations, but does not disclose any new clinical efficacy or safety data. Sobi describes pozdeutinurad as a highly selective URAT1 inhibitor with prior Phase 2 evidence of efficacy and tolerability, and NASP as a novel, sequential infusion therapy. The company also restates its operational scale, citing approximately 2,000 employees across multiple continents and SEK 28 billion in 2025 revenue.

What the data suggests

The announcement confirms that Sobi will present six abstracts at a major rheumatology conference, covering Phase 3 studies and real-world research related to uncontrolled gout. Pozdeutinurad is being studied in more than 800 patients across two 12-month, randomized, double-blind, placebo-controlled Phase 3 trials (REDUCE 1 and REDUCE 2). NASP is described as a novel, two-component infusion administered every four weeks, with ongoing DISSOLVE I/II Phase 3 trials. The only financial data disclosed is SEK 28 billion in 2025 revenue and a workforce of approximately 2,000 employees spanning Europe, North America, the Middle East, Asia, and Australia. No interim or final clinical results from the ongoing Phase 3 trials are provided, and no regulatory or commercial milestones are announced. The evidence is limited to operational scale, study design, and conference participation, with no new data to assess clinical or financial trajectory.

Analysis

The announcement is upbeat, highlighting Sobi's upcoming presentations at a major rheumatology conference and ongoing Phase 3 clinical trials for investigational gout therapies. While the tone is positive and references to 'clinically significant efficacy' and 'well-tolerated safety profile' suggest progress, no specific Phase 3 results or quantitative efficacy/safety data are disclosed—only that presentations will occur. The only realised facts are the scheduling of conference presentations, the scale and design of ongoing trials, and a single-year revenue figure. Most claims about product efficacy, patient benefit, and future impact are forward-looking or based on prior Phase 2 data without supporting numbers. There is no evidence of immediate commercial or financial benefit, and no large capital outlay is disclosed. The gap between narrative and evidence is moderate: the company frames its pipeline as promising, but measurable progress (regulatory approval, commercialisation, or profitability) remains unproven and long-dated.

Risk flags

• ●The absence of new clinical efficacy or safety data from the ongoing Phase 3 studies means there is no update on whether these investigational therapies are likely to succeed in regulatory review or commercialization. This leaves a significant evidence gap for investors assessing near-term pipeline value.
• ●The announcement relies on prior Phase 2 results and planned conference presentations, but does not provide any interim Phase 3 data or regulatory milestones. This increases uncertainty about the timing and likelihood of future approvals or market entry.
• ●The company's financial disclosure is limited to a single-year revenue figure (SEK 28 billion in 2025) and employee count, with no breakdown by segment, region, or profitability, restricting visibility into underlying business performance or the impact of its pipeline.

Bottom line

Sobi is using the ACR Convergence 2026 conference to spotlight its late-stage pipeline in uncontrolled gout, but the announcement contains no new clinical data or regulatory milestones. Investors learn that Phase 3 studies for pozdeutinurad and NASP are ongoing, with results to be discussed at the conference, but must wait for actual efficacy and safety outcomes. The company's operational scale is reaffirmed with 2,000 employees and SEK 28 billion in 2025 revenue, but there is no update on profitability, cash flow, or segment performance. The key takeaway is that Sobi remains in the data-generation phase for its gout therapies, and the investment case hinges on future clinical results and regulatory progress. Until those are disclosed, the narrative is aspirational and the risk profile remains high.

Announcement summary

(STO:SOBI) Sobi announced that six abstracts covering pozdeutinurad (AR882), nanoencapsulated sirolimus plus pegadricase (NASP), and uncontrolled gout will be presented at ACR Convergence 2026, the American College of Rheumatology annual meeting, held from 6–11 November 2026 in Orlando, Florida. The presentations include results from the Phase 3 REDUCE-2 study of pozdeutinurad, analyses from the DISSOLVE I/II Phase 3 trials of NASP, and real-world and patient preference research on uncontrolled gout in the United States. Lydia Abad-Franch, MD, Head of R&D and Medical Affairs and Chief Medical Officer at Sobi, stated that the company aims to better understand the challenges of gout and address patients' treatment needs through clinical development programmes and patient-focused research. The oral presentation titled 'Treatment with URAT1 Inhibitor Pozdeutinurad (AR882) in a Phase 3, Double-Blind, Randomized Study Lowers Serum Urate Levels in Participants with Gout' is scheduled for Wednesday 11 November from 8:15 AM to 8:30 AM. Poster presentations include evaluations of DISSOLVE I/II stopping rules for NASP, associations between clinical manifestations of gout and patient-reported outcome measures in the United States, pooled results from Phase 3 trials of NASP characterizing adverse events of special interest, patient preferences for uricase treatments in uncontrolled gout in the United States, and the impact of tophi and elevated serum urate levels on health-related quality of life and daily functioning in patients with uncontrolled gout. Gout is described as the most common form of systemic inflammatory arthritis, with uncontrolled gout characterized by serum urate levels above 6 mg/dL and persistent clinical manifestations despite oral urate-lowering therapies. Pozdeutinurad (AR882) is an investigational, once-daily oral, highly selective URAT1 inhibitor being developed to treat uncontrolled gout, with Phase 2 studies showing clinically significant efficacy, sustained reduction of serum urate levels, dissolution of tophi, and a generally well-tolerated safety profile. Pozdeutinurad is being evaluated in more than 800 patients in two 12-month, randomized, double-blind, placebo-controlled Phase 3 studies, REDUCE 1 and REDUCE 2, assessing its ability to reduce serum urate in patients with uncontrolled gout. NASP is a novel, investigational medicine designed to reduce serum urate levels in people with uncontrolled gout, administered every 4 weeks as a sequential, two-component infusion therapy with a built-in immunomodulator. Sobi has approximately 2,000 employees across Europe, North America, the Middle East, Asia, and Australia. In 2025, Sobi's revenue amounted to SEK 28 billion. Sobi's share (STO: SOBI) is listed on Nasdaq Stockholm.

Disagree with this article?